Post-earnings recap
Reported
Tue, Aug 13, 2019
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
38%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Crinetics Pharmaceuticals reported a loss per share of $0.51, but the stock rose by 2.92% following the earnings report. Investors may be reacting positively to the company's ongoing clinical trials and future potential, despite the lack of specific revenue details or guidance. The stock's increase suggests some confidence in the company's direction.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.51 | N/A | N/A |
| Revenue | N/A | N/A | N/A |
Management emphasized their commitment to advancing their pipeline. They did not provide specific guidance or revenue expectations for the future.
Management did not provide specific revenue figures or guidance for the upcoming quarters.
The focus remains on ongoing clinical trials and product development.